Lercapress (Lercanidipine Hydrochloride)

Lercanidipine selectively inhibits L‑type calcium channels on vascular smooth‑muscle cells. This blocks calcium entry, preventing muscle contraction and causing dose‑dependent vasodilation. The resulting fall in peripheral resistance leads to a sustained reduction in systemic blood pressure.

The appropriate dose of Lercapress is determined by the prescribing clinician based on the patient’s blood‑pressure profile, age, renal and hepatic function, and concomitant medications. Dosage adjustments are individualized and should follow the prescriber’s instructions.

Safety data for lercanidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lercapress belongs to the dihydropyridine calcium‑channel blocker class, which primarily causes arterial vasodilation. Compared with ACE inhibitors or beta‑blockers, it has a lower incidence of cough and may be better tolerated in patients with reactive airway disease, but it can cause peripheral edema more frequently.

Lercapress tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Do not store in humid environments such as bathrooms or near heat sources.

Lercapress is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious adverse events, although rare, include severe hypotension, myocardial infarction, angioedema and life‑threatening arrhythmias. Patients should seek immediate medical attention if they experience sudden dizziness, chest pain, swelling of the face or throat, or irregular heartbeats.

Lercapress is contraindicated in individuals with known hypersensitivity to lercanidipine or any component of the formulation. It should also be avoided in patients with severe aortic stenosis or uncontrolled heart failure unless specifically directed by a physician.